(Total Views: 462)
Posted On: 01/21/2021 11:58:30 AM
Post# of 154682
Agree, RO is likely a better answer for everyone involved (IncellDX, CYDY and patients), but as ohm pointed out this wasn't part of the original protocol for even investigational P3 monotherapy trial, much less combo that was completed over 2 years ago.
IMO perfecting the treatment for these MDR2+ patients should've been accomplished after approval and expanding the label (along with increasing the dose from 350mg to 700mg).
Precision medicine such as optimal dosing based on RO tests will likely play a part in the future and hopefully with the mono trial when it begins the pivotal P3. This will benefit IncellDX with kit sales, CYDY with lower COGS for those who respond to lower doses and patients by possibly only requiring one shot and using the proper amount of drug is always best even with a safe drug like Vyrologix.
Until CD12 results are known all the other trials are really moot points of discussion to pass the time. Best of luck to all the longs!
IMO perfecting the treatment for these MDR2+ patients should've been accomplished after approval and expanding the label (along with increasing the dose from 350mg to 700mg).
Precision medicine such as optimal dosing based on RO tests will likely play a part in the future and hopefully with the mono trial when it begins the pivotal P3. This will benefit IncellDX with kit sales, CYDY with lower COGS for those who respond to lower doses and patients by possibly only requiring one shot and using the proper amount of drug is always best even with a safe drug like Vyrologix.
Until CD12 results are known all the other trials are really moot points of discussion to pass the time. Best of luck to all the longs!
(5)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
